Catalyst Pharmaceuticals, Inc. (CPRX) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Catalyst Pharmaceuticals, Inc. (CPRX) Bundle
Simplify Catalyst Pharmaceuticals, Inc. (CPRX) valuation with this customizable DCF Calculator! Featuring real Catalyst Pharmaceuticals, Inc. (CPRX) financials and adjustable forecast inputs, you can test scenarios and uncover Catalyst Pharmaceuticals, Inc. (CPRX) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.3 | 119.1 | 140.8 | 214.2 | 398.2 | 570.1 | 816.2 | 1,168.5 | 1,672.8 | 2,394.9 |
| Revenue Growth, % | 0 | 16.39 | 18.27 | 52.1 | 85.9 | 43.17 | 43.17 | 43.17 | 43.17 | 43.17 |
| EBITDA | 31.8 | 41.3 | 52.4 | 101.8 | 119.7 | 205.9 | 294.8 | 422.0 | 604.2 | 865.0 |
| EBITDA, % | 31.11 | 34.69 | 37.2 | 47.54 | 30.06 | 36.12 | 36.12 | 36.12 | 36.12 | 36.12 |
| Depreciation | .3 | .9 | .5 | 1.5 | 32.9 | 11.8 | 16.9 | 24.1 | 34.6 | 49.5 |
| Depreciation, % | 0.29101 | 0.74351 | 0.34367 | 0.69373 | 8.26 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 |
| EBIT | 31.5 | 40.4 | 51.9 | 100.4 | 86.8 | 194.1 | 277.9 | 397.9 | 569.6 | 815.5 |
| EBIT, % | 30.81 | 33.94 | 36.85 | 46.85 | 21.8 | 34.05 | 34.05 | 34.05 | 34.05 | 34.05 |
| Total Cash | 94.5 | 140.3 | 191.3 | 298.4 | 137.6 | 486.8 | 696.9 | 997.8 | 1,428.4 | 2,045.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 10.5 | 6.0 | 6.6 | 10.4 | 53.5 | 43.7 | 62.6 | 89.6 | 128.3 | 183.6 |
| Account Receivables, % | 10.3 | 5.03 | 4.7 | 4.87 | 13.44 | 7.67 | 7.67 | 7.67 | 7.67 | 7.67 |
| Inventories | 2.0 | 4.7 | 7.9 | 6.8 | 15.6 | 21.1 | 30.2 | 43.3 | 61.9 | 88.7 |
| Inventories, % | 1.91 | 3.91 | 5.59 | 3.18 | 3.93 | 3.7 | 3.7 | 3.7 | 3.7 | 3.7 |
| Accounts Payable | 4.1 | 4.3 | 2.8 | 4.0 | 14.8 | 17.3 | 24.7 | 35.4 | 50.6 | 72.5 |
| Accounts Payable, % | 4.02 | 3.57 | 1.97 | 1.86 | 3.72 | 3.03 | 3.03 | 3.03 | 3.03 | 3.03 |
| Capital Expenditure | .0 | .0 | -1.0 | .0 | -198.5 | -57.7 | -82.6 | -118.3 | -169.4 | -242.5 |
| Capital Expenditure, % | -0.01893236 | -0.0095723 | -0.72497 | -0.01353856 | -49.85 | -10.12 | -10.12 | -10.12 | -10.12 | -10.12 |
| Tax Rate, % | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 | 24.44 |
| EBITAT | 30.1 | 72.3 | 38.9 | 79.6 | 65.6 | 165.1 | 236.4 | 338.4 | 484.5 | 693.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 22.0 | 75.2 | 33.0 | 79.5 | -141.1 | 126.0 | 150.1 | 214.9 | 307.6 | 440.4 |
| WACC, % | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 941.5 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 454 | |||||||||
| Terminal Value | 9,059 | |||||||||
| Present Terminal Value | 6,163 | |||||||||
| Enterprise Value | 7,104 | |||||||||
| Net Debt | -134 | |||||||||
| Equity Value | 7,239 | |||||||||
| Diluted Shares Outstanding, MM | 114 | |||||||||
| Equity Value Per Share | 63.63 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Catalyst Pharmaceuticals, Inc.’s (CPRX) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and saving time.
Key Features
- Comprehensive CPRX Data: Pre-filled with Catalyst Pharmaceuticals' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive, organized, and suitable for both professionals and newcomers.
How It Works
- Download: Obtain the pre-built Excel file featuring Catalyst Pharmaceuticals, Inc.'s (CPRX) financial data.
- Customize: Modify forecasts, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: Real-time updates for intrinsic value and NPV calculations as you make changes.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for Catalyst Pharmaceuticals, Inc. (CPRX)?
- Accuracy: Utilizes real Catalyst Pharmaceuticals financial data for precise calculations.
- Flexibility: Allows users to easily test and adjust inputs to fit their needs.
- Time-Saving: Avoid the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected by CFOs.
- User-Friendly: Designed for ease of use, suitable for individuals without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Accurately assess Catalyst Pharmaceuticals’ fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Catalyst Pharmaceuticals (CPRX).
- Consultants: Easily customize the template for valuation reports for clients in the pharmaceutical sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech industry.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Catalyst Pharmaceuticals, Inc. (CPRX).
- Real-World Data: Catalyst Pharmaceuticals' historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Catalyst Pharmaceuticals.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results related to Catalyst Pharmaceuticals, Inc. (CPRX).